Bio-Techne Corporation
TECH
Price:
$71.28
Market Cap:
$11.33B
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of ma...[Read more]
Industry
Biotechnology
IPO Date
1989-02-09
Stock Exchange
NASDAQ
Ticker
TECH
PE Ratio
[75.03]
ROE
[7.36%]
Current Ratio
[4.56]
Dividend Yield
[0.45%]
Enterprise Value
[11.54B]
Dividend History
The ROE as of November 2024 (TTM) for Bio-Techne Corporation (TECH) is 7.36%
According to Bio-Techne Corporation’s latest financial reports and current stock price. The company's current ROE is 7.36%. This represents a change of 299.88% compared to the average of 1.84% of the last 4 quarters.
Bio-Techne Corporation (TECH) Historical ROE (quarterly & annually)
How has TECH ROE performed in the past?
The mean historical ROE of Bio-Techne Corporation over the last ten years is 11.68%. The current 7.36% ROE has changed -36.92% with respect to the historical average. Over the past ten years (40 quarters), TECH's ROE was at its highest in in the December 2019 quarter at 9.04%. The ROE was at its lowest in in the December 2016 quarter at 0.71%.
Average
11.68%
Median
11.75%
Minimum
8.13%
Maximum
16.60%
Bio-Techne Corporation (TECH) ROE by Quarter and Year
Discovering the peaks and valleys of Bio-Techne Corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 101.41%
Maximum Annual ROE = 16.60%
Minimum Annual Increase = -46.17%
Minimum Annual ROE = 8.13%
| Year | ROE | Change |
|---|---|---|
| 2024 | 8.13% | -43.99% |
| 2023 | 14.51% | -9.30% |
| 2022 | 15.99% | 78.97% |
| 2021 | 8.94% | -46.17% |
| 2020 | 16.60% | 101.41% |
| 2019 | 8.24% | -29.04% |
| 2018 | 11.62% | 42.90% |
| 2017 | 8.13% | -31.59% |
| 2016 | 11.88% | -6.59% |
| 2015 | 12.72% | -8.82% |
Bio-Techne Corporation (TECH) Average ROE
How has TECH ROE performed in the past?
The current ROE of Bio-Techne Corporation (TECH) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
12.88%
5-year avg
12.83%
10-year avg
11.68%
Bio-Techne Corporation (TECH) ROE vs. Peers
How is TECH’s ROE compared to its peers?
Bio-Techne Corporation’s ROE is less than BioMarin Pharmaceutical Inc. (6.22%), greater than Vaxcyte, Inc. (-23.53%), greater than Liquidia Corporation (-155.77%), greater than Legend Biotech Corporation (-29.69%), greater than Seagen Inc. (-16.53%), less than Alnylam Pharmaceuticals, Inc. (323.66%), less than Exelixis, Inc. (21.26%), less than Halozyme Therapeutics, Inc. (156.40%), greater than Replimune Group, Inc. (-53.12%), greater than Nuvalent, Inc. (-28.63%), greater than Ventyx Biosciences, Inc. (-54.94%), less than Ascendis Pharma A/S (212.63%), less than United Therapeutics Corporation (19.22%), greater than Apellis Pharmaceuticals, Inc. (-103.92%), greater than BeiGene, Ltd. (-25.12%), greater than Akero Therapeutics, Inc. (-32.52%), greater than Blueprint Medicines Corporation (-47.66%), greater than Travere Therapeutics, Inc. (-541.59%),
| Company | ROE | Market cap |
|---|---|---|
| 6.22% | $12.25B | |
| -23.53% | $11.04B | |
| -155.77% | $901.38M | |
| -29.69% | $7.51B | |
| -16.53% | $43.15B | |
| 323.66% | $31.59B | |
| 21.26% | $10.17B | |
| 156.40% | $6.23B | |
| -53.12% | $1.02B | |
| -28.63% | $6.75B | |
| -54.94% | $130.81M | |
| 212.63% | $7.76B | |
| 19.22% | $16.65B | |
| -103.92% | $3.83B | |
| -25.12% | $21.35B | |
| -32.52% | $2.28B | |
| -47.66% | $5.98B | |
| -541.59% | $1.59B |
Build a custom stock screener for Bio-Techne Corporation (TECH) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Bio-Techne Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Bio-Techne Corporation (TECH) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Bio-Techne Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Bio-Techne Corporation's ROE?
How is the ROE calculated for Bio-Techne Corporation (TECH)?
What is the highest ROE for Bio-Techne Corporation (TECH)?
What is the 3-year average ROE for Bio-Techne Corporation (TECH)?
What is the 5-year average ROE for Bio-Techne Corporation (TECH)?
How does the current ROE for Bio-Techne Corporation (TECH) compare to its historical average?